Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 14.97M | 14.97M | 802.00K | 44.70M | 268.00K | 4.82M |
Gross Profit | -1.17M | 14.97M | -4.64M | 44.70M | 268.00K | 4.82M |
EBITDA | -62.56M | -55.37M | -71.06M | 6.40M | -47.87M | -14.03M |
Net Income | -69.42M | -61.07M | -73.35M | 5.34M | -50.87M | -17.71M |
Balance Sheet | ||||||
Total Assets | 129.56M | 160.33M | 214.51M | 270.20M | 280.71M | 50.67M |
Cash, Cash Equivalents and Short-Term Investments | 86.26M | 110.66M | 142.09M | 194.38M | 214.05M | 43.27M |
Total Debt | 11.99M | 12.01M | 12.98M | 8.77M | 7.22M | 46.36M |
Total Liabilities | 27.08M | 30.19M | 27.51M | 27.00M | 28.15M | 87.58M |
Stockholders Equity | 102.38M | 130.03M | 186.78M | 242.90M | 252.13M | -37.30M |
Cash Flow | ||||||
Free Cash Flow | -38.54M | -29.83M | -56.34M | -20.57M | -33.73M | -11.32M |
Operating Cash Flow | -38.12M | -28.94M | -50.92M | -14.43M | -32.58M | -11.03M |
Investing Cash Flow | -429.22K | -892.00K | -5.41M | -5.75M | -12.91M | -293.00K |
Financing Cash Flow | 1.30M | 2.16M | 1.87M | 325.00K | 222.74M | 41.44M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $7.88B | -0.12 | -39.83% | 2.18% | 21.38% | -1.56% | |
46 Neutral | $47.61M | ― | -53.78% | ― | ― | -5.42% | |
45 Neutral | $62.74M | ― | -87.74% | ― | -60.16% | ― | |
44 Neutral | $30.52M | ― | -78.25% | ― | 248.62% | 26.22% | |
41 Neutral | $21.70M | ― | -24.97% | ― | ― | 38.80% | |
40 Underperform | $26.19M | ― | -42.65% | ― | ― | -10.95% | |
39 Underperform | $62.65M | ― | -104.21% | ― | ― | 39.60% |
On June 10, 2025, Barinthus Biotherapeutics held its Annual General Meeting where all proposed matters were approved, including the re-election of directors and the appointment of auditors. The meeting also covered financial matters such as the approval of the directors’ remuneration policy and the decision not to pay dividends for the fiscal year ending December 31, 2024.